NELF-Modified CD8+ T Cells to Limit Exhaustion in Solid Tumors

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing T cell therapies are ineffective in treating solid tumors due to T cell exhaustion and insufficient memory T cell populations, leading to inadequate anti-tumor cytotoxicity.

Innovation Solution

Integrate a transgene encoding a polypeptide subunit of the negative elongation factor (NELF) complex, such as COBRA1, into the T cell genome, enhancing its expression to boost T cell efficacy against cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If T cell therapy is used to treat solid tumors, then anti-tumor immune response is activated, but T cell exhaustion occurs and memory T cell populations are insufficient

Engineering Contradiction:

Improveanti-tumor immune response efficacyVSAvoidT cell exhaustion and memory T cell persistence

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent modifies the transcriptional parameters of T cells by integrating and overexpressing NELF complex subunit genes (COBRA1, NELF-E) to alter the epigenetic landscape and transcriptional elongation efficiency. This changes the gene expression profile to prevent exhaustion markers and enhance memory T cell formation, thereby improving both the reliability and duration of anti-tumor immune response.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite genetic structure within T cells by integrating multiple transgenes encoding NELF complex subunits (COBRA1, NELF-E) along with regulatory elements. This composite genetic construct works synergistically to enhance transcriptional regulation, preventing T cell exhaustion and promoting durable memory T cell populations for sustained anti-tumor activity.

Inventive Principle:

Principle #40Composite materials

2Productivity

If transgene expression is increased to boost T cell efficacy, then anti-tumor cytotoxicity is enhanced, but genomic integration complexity increases

Engineering Contradiction:

Improveanti-tumor cytotoxicityVSAvoidgenomic integration complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent divides the transgene expression system into modular components: separate expression cassettes for COBRA1 and NELF-E subunits, each with its own promoter and regulatory elements. These segmented genetic modules are integrated at a defined genomic locus, allowing independent optimization of each subunit's expression while maintaining manageable genomic integration complexity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses a viral integration system as an intermediary mechanism to facilitate precise genomic integration of the transgenes. The viral vector serves as a mediator that delivers the genetic material to the T cell genome and mediates integration at specific loci, thereby enhancing anti-tumor cytotoxicity while controlling the complexity of genomic integration through a well-characterized biological mechanism.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12600755B2Cobra 1/NELF-B as a booster for efficacy of CD8+ T cell-based therapy

Publication Date: 2026.04.14 GEORGE WASHINGTON UNIVERSITY

AI summary

The present disclosure provides a method of generating a T cell comprising a transgene integrated at a first site within the genome of the T cell, wherein the transgene encodes a polypeptide that is a subunit of a negative elongation factor (NELF) complex. The T cells can be administered to treat cancer and infectious disease.